Home » Stocks » RCEL

Avita Therapeutics, Inc. (RCEL)

Stock Price: $20.67 USD -0.54 (-2.55%)
Updated Apr 16, 2021 4:00 PM EDT - Market closed
After-hours: $20.60 -0.07 (-0.34%) Apr 16, 7:27 PM
Market Cap 513.50M
Revenue (ttm) 19.79M
Net Income (ttm) -43.00M
Shares Out 24.84M
EPS (ttm) -1.73
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day April 16
Last Price $20.67
Previous Close $21.21
Change ($) -0.54
Change (%) -2.55%
Day's Open 21.37
Day's Range 20.59 - 21.28
Day's Volume 78,612
52-Week Range 16.87 - 30.78

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

AVITA Medical, Inc. (RCEL) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

4 days ago - Zacks Investment Research

Record Number of Accepted Abstracts Highlight Benefits of RECELL System and Reinforce Rapid Adoption by Surgeons to Advance Burn Care Record Number of Accepted Abstracts Highlight Benefits of RECELL Sys...

2 weeks ago - GlobeNewsWire

VALENCIA, Calif. and MELBOURNE, Australia, March 22, 2021 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (Nasdaq: RCEL; ASX: AVH) (“AVITA Medical”), a regenerative medicine company that is developing and comme...

3 weeks ago - GlobeNewsWire

VALENCIA, Calif. and MELBOURNE, Australia, March 01, 2021 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (Nasdaq: RCEL; ASX: AVH) (“AVITA Medical”), a regenerative medicine company that is developing and comme...

1 month ago - GlobeNewsWire

VALENCIA, Calif. and MELBOURNE, Australia, Feb. 25, 2021 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (Nasdaq: RCEL; ASX: AVH) (“AVITA Medical”), a regenerative medicine company that is developing and commer...

1 month ago - GlobeNewsWire

VALENCIA, Calif. and MELBOURNE, Australia, Feb. 24, 2021 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (Nasdaq: RCEL; ASX: AVH) (“AVITA Medical”), a regenerative medicine company that is developing and commer...

1 month ago - GlobeNewsWire

VALENCIA, Calif. and MELBOURNE, Australia, Feb. 18, 2021 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a regenerative medicine company that is developing and commercializing a techno...

2 months ago - GlobeNewsWire

VALENCIA, Calif. and MELBOURNE, Australia, Feb. 11, 2021 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX:AVH) (Company), a regenerative medicine company that is developing and commercializing...

2 months ago - GlobeNewsWire

VALENCIA, Calif. and MELBOURNE, Australia, Feb. 03, 2021 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a regenerative medicine company that is developing and commercializing a techno...

2 months ago - GlobeNewsWire

VALENCIA, Calif. and MELBOURNE, Australia, Jan. 28, 2021 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a regenerative medicine company that is developing and commercializing a techno...

2 months ago - GlobeNewsWire

AVITA Medical, Inc. (RCEL) has moved higher as of late, but there could definitely be trouble on the horizon for this company.

2 months ago - Zacks Investment Research

VALENCIA, Calif. and MELBOURNE, Australia, Dec. 28, 2020 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a regenerative medicine company that is developing and commercializing a techno...

3 months ago - GlobeNewsWire

VALENCIA, Calif., Nov. 18, 2020 (GLOBE NEWSWIRE) -- AVITA Therapeutics, Inc. (NASDAQ: RCEL, ASX:AVH), a regenerative medicine company that is developing and commercializing a technology platform that en...

5 months ago - GlobeNewsWire

AVITA's existing FDA-approved product is growing to become the standard of care in a $200 million market. The COVID-19 pandemic has been particularly disruptive for AVITA.

5 months ago - Seeking Alpha

AVITA Therapeutics, Inc. (RCEL) CEO Michael Perry on Q1 2021 Results - Earnings Call Transcript

5 months ago - Seeking Alpha

AVITA Therapeutics, Inc. (RCEL) CEO Michael Perry On Q3 2020 Results - Quick Version Earnings Call Transcript.

5 months ago - Seeking Alpha

VALENCIA, Calif., Nov. 10, 2020 (GLOBE NEWSWIRE) -- AVITA Therapeutics, Inc. (NASDAQ: RCEL, ASX:AVH), a regenerative medicine company that is developing and commercializing a technology platform that en...

5 months ago - GlobeNewsWire

VALENCIA, Calif. and MELBOURNE, Australia, Nov. 10, 2020 (GLOBE NEWSWIRE) -- AVITA Therapeutics, Inc. (NASDAQ: RCEL, ASX: AVH) (Company), a regenerative medicine company that is developing and commercia...

5 months ago - GlobeNewsWire

VALENCIA, Calif. and MELBOURNE, Australia, Nov. 05, 2020 (GLOBE NEWSWIRE) -- AVITA Therapeutics, Inc. (NASDAQ: RCEL, ASX: AVH), a regenerative medicine company that is developing and commercializing a t...

5 months ago - GlobeNewsWire

VALENCIA, Calif, and MELBOURNE, Australia, Nov. 05, 2020 (GLOBE NEWSWIRE) -- AVITA Therapeutics, Inc. (NASDAQ: RCEL, ASX:AVH), a regenerative medicine company that is developing and commercializing a te...

5 months ago - GlobeNewsWire

VALENCIA, Calif., Nov. 03, 2020 (GLOBE NEWSWIRE) -- AVITA Therapeutics, Inc. (NASDAQ: RCEL, ASX:AVH), a regenerative medicine company that is developing and commercializing a technology platform that en...

5 months ago - GlobeNewsWire

VALENCIA, Calif., Oct. 29, 2020 (GLOBE NEWSWIRE) -- AVITA Therapeutics, Inc. (NASDAQ: RCEL, ASX:AVH), a regenerative medicine company that is developing and commercializing a technology platform that en...

5 months ago - GlobeNewsWire

VALENCIA, Calif., Oct. 28, 2020 (GLOBE NEWSWIRE) -- AVITA Therapeutics, Inc. (NASDAQ: RCEL, ASX:AVH), a regenerative medicine company that is developing and commercializing a technology platform that en...

5 months ago - GlobeNewsWire

VALENCIA, Calif., Oct. 27, 2020 (GLOBE NEWSWIRE) -- AVITA Therapeutics, Inc. (NASDAQ: RCEL, ASX:AVH), a regenerative medicine company that is developing and commercializing a technology platform that en...

5 months ago - GlobeNewsWire

VALENCIA, Calif. & MELBOURNE, Australia--(BUSINESS WIRE)--AVITA Therapeutics, Inc.

8 months ago - Business Wire

These modern healthcare stocks could take care of you very well.

Other stocks mentioned: CHE
11 months ago - The Motley Fool

Find a glittering gem before the stock price takes off.

Other stocks mentioned: GLDD
1 year ago - The Motley Fool

Spectacular performer in 2019 still has a long way to go.

1 year ago - Seeking Alpha

Today's risky stocks could be tomorrow's blockbuster investments.

Other stocks mentioned: BIDU, Z, ZG
1 year ago - The Motley Fool

Seven biotechs led the way.

Other stocks mentioned: ARQL, AXSM, CNST, DRRX, EVER, ISEE, KOD ...
1 year ago - The Motley Fool

Though international markets trailed the U.S. market in 2019, there are hidden gems that crushed the S&P 500 this year on stock-specific strength.

Other stocks mentioned: AVDL, EDU, SBGL, VIPS
1 year ago - Zacks Investment Research

About RCEL

AVITA Medical Inc. operates as a commercial-stage regenerative tissue company in the United States, Australia, and the United Kingdom. It offers regenerative products to address unmet medical needs in burn injuries, trauma injuries, chronic wounds, and dermatological and aesthetics indications, including vitiligo. The company's patented and proprietary platform technology provides treatment solutions derived from the regenerative properties of a patient's own skin. Its lead product is RECELL System, a device that enables healthcare professional... [Read more...]

Industry
Medical Devices
Stock Exchange
NASDAQ
Ticker Symbol
RCEL
Full Company Profile

Financial Performance

In 2020, RCEL's revenue was 18.19 million, an increase of 59.62% compared to the previous year's 11.40 million. Losses were -42.03 million, 67.4% more than in 2019.

Financial numbers in millions AUD.
Financial Statements

Analyst Forecasts

According to 5 analysts, the average rating for RCEL stock is "Strong Buy." The 12-month stock price forecast is 41.60, which is an increase of 101.26% from the latest price.

Price Target
$41.60
(101.26% upside)
Analyst Consensus: Strong Buy